BIIB
Biogen Inc.
Is BIIB Halal?
Neurological medicines are generally permissible and March 2026 financial ratios pass the examined total-assets limits, while product and research questions remain qualitative.
What You Should Know
Biogen develops treatments for neurological and other serious conditions, including multiple sclerosis and Alzheimer's disease. Its March 31, 2026 filing shows debt at 21.33% of total assets, identifiable liquidity at 16.11%, receivables plus cash at 17.55%, and interest income at 1.53% of quarterly revenue. Product ingredients, animal research, collaborations and clinical-use details are not reducible to a universal prohibited-revenue percentage from the filing.
⚠️ Concerns
- •Interest income was 1.53% of quarterly revenue
- •Research and product development may involve animal-derived materials and animal studies requiring ethical review
- •Clinical safety, efficacy, access, pricing, patents, licensing, manufacturing, workforce and supply-chain practices require qualitative review
Current quantitative Sharia screen
Based on 10-Q figures for the period ended 2026-03-31; calculated 2026-07-14.
6,289 / 29,483
4,749 / 29,483
5,173 / 29,483
38 / 2,478
- Financial
- Pass
- Overall
- Incomplete
Debt/assets is 21.33%, liquidity/assets is 16.11%, receivables plus cash/assets is 17.55%, and disclosed interest income is 1.53%; product-level business revenue remains incomplete.
- Financial
- Pass
- Overall
- Incomplete
The examined total-assets ratios pass, but product and collaboration revenue remain incompletely screened; this is not an index-membership claim.
- Financial
- Pass
- Overall
- Incomplete
Debt/assets and identifiable liquidity/assets are below the examined 33% limits; this is a calculation against SAC ratios, not an official classification.
- Financial
- Not calculated
- Overall
- Not calculated
A properly licensed and reproducible historical market-cap series is not stored, so these methods are not estimated from a current spot price.
Business-activity disclosure
Biogen develops medicines for neurological and other serious conditions, including multiple sclerosis and Alzheimer's disease. Life-preserving healthcare activity is generally permissible, while product and research details require evidence.
Limitation: The filing does not provide a universal prohibited-revenue numerator by formulation, excipient, animal-derived input, indication, contract, collaboration or licensing arrangement.
Purification
Disclosed interest income is 1.53% of quarterly revenue, but product-level screened business revenue remains unavailable; no fixed purification percentage is prescribed.
Inputs, assumptions and primary sources
- Amounts are USD millions from Biogen's March 31, 2026 Form 10-Q and rounded to the nearest million.
- Debt is the reported $6,289 million notes-payable balance; operating lease liabilities are excluded.
- Cash is $3,383 million. Current and non-current marketable debt securities total $1,366 million; marketable equity securities are excluded.
- Receivables include accounts receivable of $1,369 million plus $421 million due from anti-CD20 therapeutic programs. Quarterly revenue is $2,478 million.
- Disclosed interest income is $37.9 million for the quarter.
- Biogen reports product, collaboration, contract manufacturing, royalty and other revenue but does not quantify formulation, ingredient, clinical-use or collaboration categories as a reproducible prohibited-revenue numerator.
This is a reproducible financial screen, not a fatwa. A failed total-assets screen can coexist with a pass under a market-cap methodology. ZakatInvest keeps the qualitative assessment separate so numerical thresholds do not erase material context.
Similar Stocks
Want to screen more assets?
Use our interactive Halal Checker to screen any stock, ETF, or crypto instantly.
Go to Halal Checker →